par Deuffic-Burban, Sylvie;Schwarzinger, Michael;Obach, Dorothée;Mallet, Vincent;Pol, Stanislas;Pageaux, Georges-Philippe;Canva, Valérie;Deltenre, Pierre
;Roudot-Thoraval, Françoise;Larrey, Dominique;Dhumeaux, Daniel;Mathurin, Philippe;Yazdanpanah, Yazdan
Référence Journal of hepatology, 61, 1, page (7-14)
Publication Publié, 2014-07
;Roudot-Thoraval, Françoise;Larrey, Dominique;Dhumeaux, Daniel;Mathurin, Philippe;Yazdanpanah, YazdanRéférence Journal of hepatology, 61, 1, page (7-14)
Publication Publié, 2014-07
Article révisé par les pairs
| Résumé : | In treatment-naive patients mono-infected with genotype 1 chronic HCV, treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy are standard-of-care. However, more efficacious direct-acting antivirals (IFN-based new DAAs) are available and interferon-free (IFN-free) regimens are imminent (2015). |



